KDEV Karolinska Development AB

Prestigious publication confirms potential of technology used by Karolinska Development's portfolio company OssDsign

Prestigious publication confirms potential of technology used by Karolinska Development's portfolio company OssDsign
EN
14/10/2020

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development's portfolio company Modus Therapeutics receives...

Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in Q4 2025, in line with the company’s development timeline. Modus Therapeutics, listed on Nasdaq First North Growt...

November 4, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag Modus Therapeutics får klartecke...

Karolinska Developments portföljbolag Modus Therapeutics får klartecken att starta den andra delen av en klinisk fas 2-studie i kronisk njursjukdom med anemi STOCKHOLM, 4 november, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har fått regulatoriskt godkännande att inleda den andra delen av bolagets kliniska fas 2-studie med sevuparin som en ny potentiell behandling av kronisk njursjukdom med anemi. Studien kommer att initieras under fjärde kvartalet 2025, vilket är i linje med Modus Therapeutics kommunicerade tidsplan. Modus ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 ...

Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures Stockholm, Sweden – November 3, 2025 – Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured as a tranched convertible loan from Sound Bioventures.The investment supports continued clinical development of BT-101, a pioneering stem cell-based therapy for Osteogenesis imperfecta (OI), also known as Brittle bone disease. BOOST Pharma, a clinical-stage biopharmaceuti...

November 3, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag BOOST Pharma tillförs SEK 34 mil...

Karolinska Developments portföljbolag BOOST Pharma tillförs SEK 34 miljoner genom riktad emission till Sound Bioventures STOCKHOLM, SVERIGE 3 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget BOOST Pharma har tagit in 34 miljoner kronor, genom ett trancherat konvertibellån från Sound Bioventures. Investeringen stödjer fortsatt klinisk utveckling av BT-101, en innovativ stamcellsbaserad behandling av Osteogenesis imperfecta (OI), även kallad Brittle bone disease. BOOST Pharma, ett biopharma-bolag i klinisk utvecklingsfas, utvecklar BT-101 so...

November 3, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company BOOST Pharma presents posit...

Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta STOCKHOLM, SWEDEN, October 31, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase 1/2 trial with the company’s cell therapy BT-101 targeting the rare bone disease Osteogenesis imperfecta. The new results comprise two-year follow-up data from the trial and were selected for presentation at the prestigious 15th International Conferenc...

October 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch